Tandem Diabetes Care Inc. (TD5A)
Summary
TD5A Chart
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up
Tandem Diabetes shares jump 19.1% after a narrower-than-expected Q2 loss, as higher pump shipments and a 57% gross margin offset a slight revenue miss.
Tandem Diabetes Care Q2 Earnings Call Highlights
Tandem Diabetes Care NASDAQ: TNDM reported second-quarter results that included record sales, pump shipments and gross margin for a second quarter, while management highlighted early progress in its transition to pharmacy-channel reimbursement and continued development of new insulin-delivery technologies.
Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript
Tandem Diabetes Care Inc. (TD5A) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tandem Diabetes Care Inc. ever had a stock split?
Tandem Diabetes Care Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | John F. Sheridan CEO | XSTU Exchange | 875372203 CUSIP |
| US Country | 2,500 Employees | 10 Oct 2017 Last Dividend | 10 Oct 2017 Last Split | 14 Nov 2013 IPO Date |
Overview
Tandem Diabetes Care, Inc. is a leading medical device company dedicated to enhancing the lives of individuals with diabetes worldwide through innovative technology solutions. Originating as Phluid Inc., the company was rebranded to Tandem Diabetes Care, Inc. in January 2008, reflecting its focused mission on diabetes management solutions. Since its incorporation in 2006, Tandem Diabetes Care has been committed to development, design, and commercialization efforts centered around advancing diabetes care. Headquartered in San Diego, California, Tandem offers a wide array of products that significantly improve the management of diabetes for its users in the United States and across the globe.
Products and Services
- t:slim X2 Insulin Delivery System: The flagship product of Tandem, the t:slim X2, is an innovative insulin pump platform that enhances insulin management. It integrates continuous glucose monitoring (CGM) sensor information, displaying it directly on the home screen of the pump for convenience and ease-of-use. This integration facilitates real-time diabetes management by allowing for immediate adjustments.
- Tandem Mobi Insulin Pump: As an automated insulin delivery system, the Tandem Mobi pump represents the latest in Tandem's product innovations. Designed to provide a compact, flexible insulin delivery solution, it supports users in achieving optimal glycemic control with minimal manual intervention.
- Single-Use Products: Tandem also offers essential single-use products such as cartridges, which are integral for insulin storage and delivery, and infusion sets that securely connect the insulin pump to the user. These consumable components are designed for ease-of-use and reliability.
- Tandem Device Updater: Understanding the need for continuous improvement, the Tandem Device Updater enables users to update their pump’s software conveniently from a personal computer. This feature ensures that users have access to the latest functionalities and improvements without needing a new device.
- Tandem Source: A web-based data management platform, Tandem Source, provides users and healthcare providers with a comprehensive visual display of diabetes therapy management data. This platform integrates data from the pumps, CGMs, and supported blood glucose meters, facilitating a holistic view of the user's diabetes management.
- Sugarmate: This mobile application complements Tandem’s product ecosystem by helping users visualize their diabetes therapy data in an easily accessible format. Sugarmate enables users to track their glucose levels, insulin doses, and more, directly from their smartphones, fostering more informed diabetes management decisions.
